<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org).">
  <meta name="generator" content="bookdown 0.0.79 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="github-repo" content="shanmdphd/PAPER" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-07-14">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="opening-remark.html">
<link rel="next" href="second-session.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>2</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="2.1" data-path="opening-remark.html"><a href="opening-remark.html"><i class="fa fa-check"></i><b>2.1</b> Opening Remark</a></li>
<li class="chapter" data-level="2.2" data-path="first-session.html"><a href="first-session.html"><i class="fa fa-check"></i><b>2.2</b> First Session</a><ul>
<li class="chapter" data-level="2.2.1" data-path="first-session.html"><a href="first-session.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>2.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="2.2.2" data-path="first-session.html"><a href="first-session.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>2.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="2.2.3" data-path="first-session.html"><a href="first-session.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>2.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="second-session.html"><a href="second-session.html"><i class="fa fa-check"></i><b>2.3</b> Second Session</a><ul>
<li class="chapter" data-level="2.3.1" data-path="second-session.html"><a href="second-session.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>2.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="2.3.2" data-path="second-session.html"><a href="second-session.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>2.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="2.3.3" data-path="second-session.html"><a href="second-session.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>2.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="2.3.4" data-path="second-session.html"><a href="second-session.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>2.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>3</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="3.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html"><i class="fa fa-check"></i><b>3.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="3.1.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-1--------"><i class="fa fa-check"></i><b>3.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="3.1.2" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-2----"><i class="fa fa-check"></i><b>3.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html"><i class="fa fa-check"></i><b>3.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="3.2.1" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>3.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="3.2.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>3.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="3.2.3" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-3-------"><i class="fa fa-check"></i><b>3.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>4</b> ACREP</a><ul>
<li class="chapter" data-level="4.1" data-path="observational-study.html"><a href="observational-study.html"><i class="fa fa-check"></i><b>4.1</b> Observational Study</a><ul>
<li class="chapter" data-level="4.1.1" data-path="observational-study.html"><a href="observational-study.html#contents"><i class="fa fa-check"></i><b>4.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html"><i class="fa fa-check"></i><b>4.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="4.2.1" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-yes"><i class="fa fa-check"></i><b>4.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="4.2.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-no"><i class="fa fa-check"></i><b>4.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="4.2.3" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#contents-1"><i class="fa fa-check"></i><b>4.2.3</b> Contents</a></li>
<li class="chapter" data-level="4.2.4" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#conclusion"><i class="fa fa-check"></i><b>4.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html"><i class="fa fa-check"></i><b>4.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="4.3.1" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>4.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="4.3.2" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---biomarker"><i class="fa fa-check"></i><b>4.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="-.html"><a href="-.html"><i class="fa fa-check"></i><b>4.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="4.5" data-path="-clinical-prediction-model-individual-riskoutcome-probability-.html"><a href="-clinical-prediction-model-individual-riskoutcome-probability-.html"><i class="fa fa-check"></i><b>4.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="4.6" data-path="web-r-org.html"><a href="web-r-org.html"><i class="fa fa-check"></i><b>4.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="4.6.1" data-path="web-r-org.html"><a href="web-r-org.html#contents-2"><i class="fa fa-check"></i><b>4.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="prism.html"><a href="prism.html"><i class="fa fa-check"></i><b>5</b> Prism</a><ul>
<li class="chapter" data-level="5.1" data-path="morning.html"><a href="morning.html"><i class="fa fa-check"></i><b>5.1</b> Morning</a><ul>
<li class="chapter" data-level="5.1.1" data-path="morning.html"><a href="morning.html#lim-covariate-model"><i class="fa fa-check"></i><b>5.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="5.1.2" data-path="morning.html"><a href="morning.html#fda---lee"><i class="fa fa-check"></i><b>5.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="5.1.3" data-path="morning.html"><a href="morning.html#pfizer"><i class="fa fa-check"></i><b>5.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="5.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html"><i class="fa fa-check"></i><b>5.2</b> PRISM Afternoon</a><ul>
<li class="chapter" data-level="5.2.1" data-path="prism-afternoon.html"><a href="prism-afternoon.html#kim"><i class="fa fa-check"></i><b>5.2.1</b> Kim</a></li>
<li class="chapter" data-level="5.2.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>5.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="5.2.3" data-path="prism-afternoon.html"><a href="prism-afternoon.html#mbdd"><i class="fa fa-check"></i><b>5.2.3</b> MBDD</a></li>
<li class="chapter" data-level="5.2.4" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>5.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="5.2.5" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>5.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><a href="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><i class="fa fa-check"></i><b>6</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="6.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html"><i class="fa fa-check"></i><b>6.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="6.1.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>6.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="6.1.2" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>6.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><i class="fa fa-check"></i><b>6.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="6.2.1" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#considerations-for-drug-development-for-rare-diseases-cases-of-inborn-errors-of-metabolism"><i class="fa fa-check"></i><b>6.2.1</b> Considerations for drug development for rare diseases : Cases of inborn errors of metabolism</a></li>
<li class="chapter" data-level="6.2.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#role-of-pharmacometrics-in-the-development-of-orphan-drugs"><i class="fa fa-check"></i><b>6.2.2</b> Role of pharmacometrics in the development of orphan drugs</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="session-3-lessons-and-learned-rd-for-rare-disease.html"><a href="session-3-lessons-and-learned-rd-for-rare-disease.html"><i class="fa fa-check"></i><b>6.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a></li>
<li class="chapter" data-level="6.4" data-path="session-4-asan-initia-tives-for-rare-disease.html"><a href="session-4-asan-initia-tives-for-rare-disease.html"><i class="fa fa-check"></i><b>6.4</b> Session 4 Asan initia tives for rare disease</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="first-session" class="section level2">
<h2><span class="header-section-number">2.2</span> First Session</h2>
<ul>
<li>Chair : Deborah Chee(KoNECT)</li>
</ul>
<div id="precision-medicine-a-clinical-pharmacological-perspective" class="section level3">
<h3><span class="header-section-number">2.2.1</span> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</h3>
<ul>
<li>Speaker: <a href="https://en.wikipedia.org/wiki/Munir_Pirmohamed">Munir Pirmohamed</a> (University of Liverpool, UK)</li>
<li>Fava beans - Favism G6PD deficiency - withrawal of antimalarials</li>
<li>2015 Obama Precision Medicine $215m / 2016 China $8b</li>
<li>Phenotypic definition(current standard) - Molecular definition (disease stratification) - Drug variability</li>
<li>Mandatory genomic testing - EMA SmPC</li>
<li>Pharmacogenomics Journal (2015) 1-10</li>
<li>Crizotinib vs CTx in advanced ALK+ lung cancer (NEJM 2013)</li>
<li>Novel trial design (Nature 2015)</li>
</ul>
<ol style="list-style-type: decimal">
<li>Umbrella trial (single tumor - multiple arm - multiple drugs)</li>
<li>Basket study</li>
</ol>
<ul>
<li>Support of humen genetic evidence for approved drug indication (Nature Genetics)</li>
<li>Sclerosteosis - skeletal overgrowth and syndactyly, AR , mutations in SOST gene - target sclerostin</li>
<li>anti-sclerostin Ab (ROMOSOZUMAB, BLOSOZUMAB) - bone density increase - mouse</li>
<li>New cardiovascular targets</li>
<li>PCSK9 - GOF-&gt;LDL-C increase &amp; CVD</li>
<li>ANGPTL4</li>
<li>HLA-genotype and carbamazepine-induced cutaneous ADR: systemic review (CPT,2012)</li>
<li>ITCH (Drug hypersensitivity)</li>
<li>Phase I, II - very strong association (Manhattan plot) - GWAS - ALK(germline polymorphism-&gt; T cell expansion)</li>
<li>SJS GWAS (Genin 2011) <a href="http://www.ncbi.nlm.nih.gov/pubmed/21801394" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/21801394</a></li>
<li>Skin, Liver</li>
<li>CBZ-induced hypersensitivity vs CBZ-tolerant patients</li>
<li>HLA-A*31:01(thirtyone o one)</li>
<li>HLA and ADR</li>
<li>The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. (2016) <a href="http://www.ncbi.nlm.nih.gov/pubmed/26478982" class="uri">http://www.ncbi.nlm.nih.gov/pubmed/26478982</a></li>
<li>Somatic genomes -&gt; microbiome is also important</li>
<li>Digoxin and antibiotics (1981, NEJM) -&gt; (2013 Science) Cardiac drug inactivation by human gut bacteria</li>
<li>Microbiome and Cancer Immunotherapy - Snyder, Science Nov 2015</li>
<li>Two books introduced.</li>
</ul>
<ol style="list-style-type: decimal">
<li>Prescription for nhs</li>
<li>clinical pharma dynamic medical specialty</li>
</ol>
</div>
<div id="the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice" class="section level3">
<h3><span class="header-section-number">2.2.2</span> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</h3>
<ul>
<li>Speaker: Shiew-Mei Huang (North Potomac, MD, USA)</li>
<li>CPIC (Clinical pharmacogenetics guidelines)</li>
<li>IFNL3(IL28B) HCV treatment Favorable response = 77% Asian (Genotype CC)</li>
<li>Paving the way for Personalized Medicine (Oct 2013)</li>
<li>Avacavir HLA-B*5701 (RCT) Utility of pharmacogenetic tests</li>
<li>Munir mentioned - CBZ &amp; HLA-B*1502</li>
<li>ASCO meeting - CTx vs Targeted therapy - Umbrella study</li>
<li>Drug labeling “FDA-approved test”</li>
<li>XALKORI - Crizotinib and ALK</li>
<li>CPT Feb 2016 - Precision Medicine , “Companion Diagnostics” Something unique to conduct , “Complementary diagnostics”</li>
<li>Eliglustat and CYP2D6 , Drug labeling</li>
<li>Center for Device</li>
<li>Integral to the future of personalized or precision medicine</li>
<li>NGS</li>
<li>PrecisionFDA initiative</li>
<li>23andMe - Drug response , Confidence</li>
<li>Cleared or approved FDA</li>
<li>CLIA-certified laboratory</li>
</ul>
<div id="my-question" class="section level4">
<h4><span class="header-section-number">2.2.2.1</span> My Question</h4>
<ul>
<li>One NGS - individual test to is there a review of all-in-one Test in progress?</li>
</ul>
</div>
</div>
<div id="the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology" class="section level3">
<h3><span class="header-section-number">2.2.3</span> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</h3>
<ul>
<li>Speaker: Eric Chun Yong Chan (National University of Singapore)</li>
<li>Liver - major organ for disposition and detoxification</li>
<li>60% (explanble) vs 40% (how about this?) - superorganism</li>
<li>400 different species (~1.5kg)</li>
<li>Haiser (2012, Science) Gut microbe - drug, host interaction</li>
<li>TOC: 1 DMD paper , 2 in-house project</li>
<li>DMD - reduction, hydrolysis</li>
<li>absorption - simvastatin - poor responder, average, good 10% 80% 10%
<ul>
<li>OATP1B1 in liver and intestine</li>
<li>Possibility of competition between simvastatin and bile acids for hepatic uptake by transporter</li>
<li>antibiotics - nitro-reduction by gut microbiota inhibition</li>
<li>Therapeutic fficacy - DDI</li>
</ul></li>
<li>PCA analysis PNAS 2009 - significant differences in concentration</li>
<li>PNAS 2009 inverse corr - p-cresol &lt;-&gt; AAP</li>
<li>2nd part - Tacrine - first drug approved for AD. Toxicological manifestation - increased AST/ALT</li>
<li>Interindividual variability. why?</li>
<li>Tacrine metabolism - hydroxylation / glucuronide</li>
<li>mitochondrial toxicity and hypoxia-reoxygenation</li>
<li>part I~V</li>
<li>Tacrine-induced transaminitis</li>
<li>EXT - CMax,AUC high why? - phase II metabolite?</li>
<li>host gene - mRNA</li>
<li>GC/TO</li>
<li>PCA analysis principal component analysis</li>
<li>NORMAL Lactobacillus</li>
<li>EXT Bacteriode Blautia</li>
<li>Metagenome level</li>
<li>Liver - Tacrine-&gt; TacrineNGlucuronide</li>
</ul>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="opening-remark.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="second-session.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-14-2016-KSCPT.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
